CBL — Control Bionics Income Statement
0.000.00%
Last trade - 00:00- AU$9.07m
- AU$8.55m
- AU$6.03m
- 16
- 44
- 35
- 24
Annual income statement for Control Bionics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.3 | 4.09 | 4.72 | 5.91 | 6.03 |
| Cost of Revenue | |||||
| Gross Profit | 2.59 | 2.66 | 2.74 | 3.98 | 4.58 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.3 | 7.67 | 10.8 | 11.5 | 11.9 |
| Operating Profit | -1 | -3.58 | -6.08 | -5.61 | -5.86 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.01 | -3.55 | -6.1 | -5.63 | -5.91 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.01 | -3.55 | -6.1 | -5.63 | -5.91 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.01 | -3.55 | -6.1 | -5.63 | -5.91 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.01 | -3.55 | -6.1 | -5.63 | -5.91 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.011 | -0.045 | -0.065 | -0.052 | -0.037 |
| Dividends per Share |